Codes ATC:
V03AF01
EMLc
Indication
Osteosarcoma of bone and articular cartilage of other specified sites
Code ICD11:
2C21.Y
INN
Mesna
Type de médicament
Chemical agent
Type de liste
Liste complémentaire
(EML)
(EMLc)
(EMLc)
Formulations
Parenteral > General injections > IV:
100 mg per mL in 4 mL ampoule ;
100 mg per mL in 10 mL ampoule
Oral > Solid: 400 mg ; 600 mg
Oral > Solid: 400 mg ; 600 mg
Historique des statuts LME
Ajouté pour la première fois en 2015
(TRS
994)
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite
sur les brevets.
Résumé des preuves et recommandation du comité d'experts
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for mesna on the complementary list of the EML and EMLc for use in treatment protocols for osteosarcoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for osteosarcoma is attached.